sign in sign up
<<
Home , Clonazolam, Flubromazolam, Lorcaserin, Solriamfetol, Thiafentanil

MISSISSIPPI LEGISLATURE REGULAR SESSION 2020

By: Senator(s) Jordan, Jackson (11th) To: Drug Policy; Judiciary, Division A

SENATE BILL NO. 2694

1 AN ACT TO AMEND SECTION 41-29-113, MISSISSIPPI CODE OF 1972, 2 TO ADD , , AND 3 TO SCHEDULE I BECAUSE THESE DRUGS HAVE NO LEGITIMATE MEDICAL USE 4 AND HAVE HIGH POTENCY WITH GREAT POTENTIAL TO CAUSE HARM; TO AMEND 5 SECTION 41-29-115, MISSISSIPPI CODE OF 1972, TO REVISE SCHEDULE II 6 TO CLARIFY THE CHEMICAL NAME OF THIAFENTANIL; TO AMEND SECTION 7 41-29-119, MISSISSIPPI CODE OF 1972, TO ADD TO SCHEDULE IV THE 8 DRUGS BREXANOLONE (ZULRESSO) AND SOLRIAMFETOL (SUNOSI) BECAUSE 9 THESE DRUGS RECENTLY HAVE BEEN APPROVED FOR MEDICAL USE BY THE 10 FEDERAL DRUG ADMINISTRATION; AND FOR RELATED PURPOSES. 11 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MISSISSIPPI:

12 SECTION 1. Section 41-29-113, Mississippi Code of 1972, is 13 amended as follows: 14 41-29-113.

15 SCHEDULE I 16 (a) Schedule I consists of the drugs and other substances, 17 by whatever official name, common or usual name, chemical name, or

18 brand name designated, that is listed in this section.

19 (b) Opiates. Unless specifically excepted or unless listed 20 in another schedule, any of the following opiates, including their 21 isomers, esters, , salts and salts of isomers, esters and

S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ G1/2 20/SS08/R210 PAGE 1 (csq\tb) 22 ethers, whenever the existence of these isomers, esters, ethers 23 and salts is possible within the specific chemical designation: 24 (1) Acetyl--methylfentanyl; 25 (2) Acetyl 26 N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide; 27 (3) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)

28 cyclohexylmethyl]benzamide); 29 (4) Acetylmethadol; 30 (5) Allylprodine; 31 (6) Alphacetylmethadol, except levo-alphacetylmethadol 32 (levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM); 33 (7) Alphameprodine; 34 (8) Alphamethadol;

35 (9) Alpha-methylfentanyl; 36 (10) Alpha-methylthiofentanyl; 37 (11) Benzethidine; 38 (12) Betacetylmethadol; 39 (13) Beta-hydroxyfentanyl;

40 (14) Beta-hydroxy-3-methylfentanyl; 41 (15) Betameprodine;

42 (16) Betamethadol; 43 (17) Betaprodine; 44 (18) Butyrl fentanyl 45 (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide); 46 (19) Clonitazene;

S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 2 (csq\tb) 47 (20) ; 48 (21) Diampromide; 49 (22) Diethylthiambutene; 50 (23) Difenoxin; 51 (24) ; 52 (25) Dimepheptanol;

53 (26) Dimethylthiambutene; 54 (27) Dioxaphetyl butyrate; 55 (28) ; 56 (29) Ethylmethylthiambutene; 57 (30) Etonitazene; 58 (31) Etoxeridine; 59 (32) Fentanyl-related substances, meaning any substance

60 not otherwise listed under another schedule and for which no 61 exemption or approval is in effect under Section 505 of the 62 Federal Food, Drug, and Cosmetic Act [21 USC 355] that is 63 structurally related to fentanyl by one or more of the following 64 modifications:

65 (A) Replacement of the phenyl portion of the 66 phenethyl group by any monocycle, whether or not further

67 substituted in or on the monocycle; 68 (B) Substitution in or on the phenethyl group with 69 alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, amino or nitro 70 groups;

S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 3 (csq\tb) 71 (C) Substitution in or on the ring with 72 alkyl, alkenyl, alkoxyl, ester, , hydroxyl, halo, haloalkyl, 73 amino or nitro groups; 74 (D) Replacement of the aniline ring with any 75 aromatic monocycle whether or not further substituted in or on the 76 aromatic monocycle; and/or

77 (E) Replacement of the N-propionyl group by 78 another acyl group. 79 Fentanyl-related substances include, but are not limited to, 80 cyclopropyl fentanyl, 81 (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide); 82 Furanyl-Fentanyl, 83 (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide);

84 valeryl fentanyl, 85 (N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide); 86 para-fluorobutyryl fentanyl, 87 (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide); 88 para-methoxybutyryl fentanyl,

89 (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide); 90 para-chloroisobutyryl fentanyl,

91 (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide); 92 isobutyryl fentanyl, 93 (N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide);

S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 4 (csq\tb) 94 cyclopentyl fentanyl, 95 (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide); 96 and 97 ocfentanil, 98 (N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetami 99 de);

100 (33) Furethidine; 101 (34) Hydroxypethidine; 102 (35) (including the optical and geometric 103 isomers); 104 (36) Levomoramide; 105 (37) Levophenacylmorphan; 106 (38) 3-methylfentanyl;

107 (39) 3-methylthiofentanyl; 108 (40) Morpheridine; 109 (41) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine); 110 (42)

111 N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylprop 112 ionamide, its isomers, esters, ethers, salts and salts of isomers, 113 esters and ethers (other names: beta-hydroxythiofentanyl);

114 (43) Noracymethadol; 115 (44) Norlevorphanol; 116 (45) Normethadone; 117 (46) Norpipanone; 118 (47) Para-fluorofentanyl;

S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 5 (csq\tb) 119 (48) PEPAP 120 (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine); 121 (49) Phenadoxone; 122 (50) Phenampromide; 123 (51) Phenomorphan; 124 (52) Phenoperidine;

125 (53) ; 126 (54) Proheptazine; 127 (55) Properidine; 128 (56) ; 129 (57) Racemoramide; 130 (58) ; 131 (59) ;

132 (60) Trimeperidine; 133 (61) U-47700, 134 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide.

135 (c) derivatives. Unless specifically excepted or 136 unless listed in another schedule, any of the following opium

137 derivatives, their salts, isomers and salts of isomers, whenever 138 the existence of these salts, isomers and salts of isomers is

139 possible within the specific chemical designation: 140 (1) Acetorphine; 141 (2) ; 142 (3) ; 143 (4) methylbromide;

S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 6 (csq\tb) 144 (5) Codeine-N-Oxide; 145 (6) ; 146 (7) ; 147 (8) ; 148 (9) Drotebanol; 149 (10) (except hydrochloride salt);

150 (11) ; 151 (12) ; 152 (13) Methyldesorphine; 153 (14) Methyldihydromorphine; 154 (15) Monoacetylmorphine; 155 (16) methylbromide; 156 (17) Morphine methylsulfonate;

157 (18) Morphine-N-Oxide; 158 (19) Myrophine; 159 (20) ; 160 (21) ; 161 (22) Normorphine;

162 (23) Pholcodine; 163 (24) Thebacon.

164 (d) Hallucinogenic substances. Unless specifically excepted 165 or unless listed in another schedule, any material, compound, 166 mixture or preparation which contains any quantity of the 167 following substances, their salts, isomers (whether optical, 168 positional, or geometric) and salts of isomers, whenever the

S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 7 (csq\tb) 169 existence of these salts, isomers and salts of isomers is possible 170 within the specific chemical designation: 171 (1) Alpha-ethyltryptamine; 172 (2) 4-bromo-2,5-dimethoxy-; 173 (3) 4-bromo-2,5-dimethoxyphenethylamine; 174 (4) 2,5-;

175 (5) 2,5-dimethoxy-4-ethylamphetamine (DOET); 176 (6) 2,5-dimethoxy-4-(n)-propylthiophenethylamine 177 (-T-7); 178 (7) 4-methoxyamphetamine; 179 (8) 5-methoxy-3,4-methylenedioxy-amphetamine; 180 (9) 4-methyl-2,5-dimethoxy-amphetamine; 181 (10) 3,4-methylenedioxy amphetamine;

182 (11) 3,4-methylenedioxymethamphetamine (MDMA); 183 (12) 3,4-methylenedioxy-N-ethylamphetamine (also known 184 as N-ethyl-alpha-methyl-3,4(methylenedioxy), N-ethyl 185 MDA, MDE, MDEA); 186 (13) N-hydroxy-3,4-methylenedioxyamphetamine (also

187 known as N-hydroxy MDA, N-OHMDA, and 188 N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine);

189 (14) 3,4,5-trimethoxy amphetamine; 190 (15) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT); 191 (16) Alpha-methyltryptamine (also known as AMT); 192 (17) Bufotenine; 193 (18) ;

S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 8 (csq\tb) 194 (19) Dimethyltryptamine; 195 (20) 5-methoxy-N,N- (5-MeO-DIPT); 196 (21) ; 197 (22) Lysergic acid diethylamide (LSD); 198 (23) (A) Marijuana ( contained in a legend 199 drug product approved by the Federal Food and Drug Administration

200 or obtained under Section 41-29-136 is exempt under Schedule I); 201 (B) Hashish; 202 (24) ; 203 (25) ; 204 (26) Peyote; 205 (27) N-ethyl-3-piperidyl benzilate; 206 (28) N-methyl-3-piperidyl benzilate;

207 (29) ; 208 (30) Psilocyn; 209 (31) , meaning 210 tetrahydrocannabinols contained in a plant of the genus 211 (cannabis plant), as well as the synthetic equivalents of the

212 substances contained in the cannabis plant, or in the resinous 213 extractives of such plant, and/or synthetic substances,

214 derivatives, and their isomers with similar chemical structure and 215 pharmacological activity to those substances contained in the 216 plant such as the following: 217 (A) 1 cis or trans ; 218 (B) 6 cis or trans tetrahydrocannabinol;

S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 9 (csq\tb) 219 (C) 3,4 cis or trans tetrahydrocannabinol. 220 (Since nomenclature of these substances is not 221 internationally standardized, compounds of these structures, 222 regardless of atomic positions, are covered.) 223 ("Tetrahydrocannabinols" excludes dronabinol and .) 224 However, the following products are exempted from control:

225 (i) THC-containing industrial products made 226 from cannabis stalks (e.g., paper, rope and clothing); 227 (ii) Processed cannabis plant materials used 228 for industrial purposes, such as fiber retted from cannabis stalks 229 for use in manufacturing textiles or rope; 230 (iii) Animal feed mixtures that contain 231 sterilized cannabis seeds and other ingredients (not derived from

232 the cannabis plant) in a formula designed, marketed and 233 distributed for nonhuman consumption; 234 (iv) Personal care products that contain oil 235 from sterilized cannabis seeds, such as shampoos, soaps, and body 236 lotions (if the products do not cause THC to enter the human

237 body); and 238 (v) Processed cannabis plant extract, oil or

239 resin with a minimum ratio of twenty-to-one cannabidiol to 240 tetrahydrocannabinol (20:1 cannabidiol:tetrahydrocannabinol), and 241 diluted so as to contain at least fifty (50) milligrams of 242 cannabidiol per milliliter, with not more than two and one-half 243 (2.5) milligrams of tetrahydrocannabinol per milliliter;

S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 10 (csq\tb) 244 (32) ; 245 (33) Ethylamine analog of phencyclidine (PCE); 246 (34) analog of phencyclidine (PHP, PCPy); 247 (35) Thiophene analog of phencyclidine; 248 (36) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine (TCPy); 249 (37) 4-methylmethcathinone ();

250 (38) 3,4-methylenedioxypyrovalerone (MDPV); 251 (39) 2-(2,5-dimethoxy-4-ethylphenyl)ethanamine (2C-E); 252 (40) 2-(2,5-dimethoxy-4-methylphenyl)ethanamine (2C-D); 253 (41) 2-(4-chloro-2,5-dimethoxyphenyl)ethanamine (2C-C); 254 (42) 2-(4-iodo-2,5-dimethoxyphenyl)ethanamine (2C-I); 255 or 2,5-dimethoxy-4-iodophenethylamine; 256 (43) 2-[4-(ethylthio)-2,5-dimethoxyphenyl]ethanamine

257 (2C-T-2); 258 (44) 259 2-[4-(isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4); 260 (45) 2-(2,5-dimethoxyphenyl)ethanamine (2C-H); 261 (46) 2-(2,5-dimethoxy-4-nitro-phenyl)ethanamine (2C-N);

262 (47) 2-(2,5-dimethoxy-4-(n)-propylphenyl)ethanamine 263 (2C-P);

264 (48) 3,4-methylenedioxy-N-methylcathinone(); 265 (49) 266 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine 267 (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36);

S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 11 (csq\tb) 268 (50) 269 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine 270 (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82); 271 (51) 272 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine or 273 N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I;

274 Cimbi-5); 275 (52) 7-bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1, 276 4-benzodiazepin-2-one (also known as ); 277 (53) 7-(2-chlorophenyl)-4-ethyl-13-methyl-3-thia-1,8, 278 11,12-tetraazatricyclo[8.3.0.0]trideca-2(6),4,7,10,12-pentaene 279 (also known as ); 280 (54) ;

281 (55) Synthetic . Unless specifically 282 excepted or unless listed in another schedule, any material, 283 compound, mixture, or preparation which contains any quantity of a 284 synthetic found in any of the following chemical 285 groups, whether or not substituted to any extent, or any of those

286 groups which contain any synthetic cannabinoid salts, isomers, or 287 salts of isomers, whenever the existence of such salts, isomers,

288 or salts of isomers is possible within the specific chemical 289 designation, including all synthetic cannabinoid chemical 290 analogues in such groups: 291 (A) (6aR,10aR)-9-(hydroxymethyl)-6, 292 6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]

S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 12 (csq\tb) 293 chromen-1-ol (also known as HU-210 or 294 1,1-dimethylheptyl-11-hydroxy-delta8-tetrahydrocannabinol); 295 (B) Naphthoylindoles and naphthylmethylindoles, 296 being any compound structurally derived from 3-(1-naphthoyl)indole 297 or 1H-indol-3-yl-(1-naphthyl)methane, whether or not substituted 298 in the indole ring to any extent, or in the naphthyl ring to any

299 extent; 300 (C) Naphthoylpyrroles, being any compound 301 structurally derived from 3-(1-naphthoyl)pyrrole, whether or not 302 substituted in the pyrrole ring to any extent, or in the naphthyl 303 ring to any extent; 304 (D) Naphthylmethylindenes, being any compound 305 structurally derived from 1-(1-naphthylmethyl)indene, whether or

306 not substituted in the indene ring to any extent or in the 307 naphthyl ring to any extent; 308 (E) Phenylacetylindoles, being any compound 309 structurally derived from 3-phenylacetylindole, whether or not 310 substituted in the indole ring to any extent or in the phenyl ring

311 to any extent; 312 (F) Cyclohexylphenols, being any compound

313 structurally derived from 2-(3-hydroxycyclohexyl), whether

314 or not substituted in the cyclohexyl ring to any extent or in the 315 phenolic ring to any extent; 316 (G) Benzoylindoles, whether or not substituted in 317 the indole ring to any extent or in the phenyl ring to any extent;

S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 13 (csq\tb) 318 (H) Adamantoylindoles, whether or not substituted 319 in the indole ring to any extent or in the adamantoyl ring system 320 to any extent; 321 (I) Tetrahydro derivatives of cannabinol and 322 3-alkyl homologues of cannabinol or of its tetrahydro derivatives, 323 except where contained in cannabis or cannabis resin;

324 (J) 3-Cyclopropylmethanone indole or 325 3-Cyclobutylmethanone indole or 3-Cyclopentylmethanone indole by 326 substitution at the atom of the indole ring, whether or 327 not further substituted in the indole ring to any extent, whether 328 or not substituted on the cyclopropyl, cyclobutyl or cyclopentyl 329 rings to any extent; 330 (K) Quinolinyl ester indoles, being any compound

331 structurally derived from 1H-indole-3carboxylic acid-8-quinolinyl 332 ester, whether or not substituted in the indole ring to any extent 333 or the quinolone ring to any extent; 334 (L) 3-carboxamide-1H-indazoles, whether or not 335 substituted in the indazole ring to any extent and substituted to

336 any degree on the carboxamide nitrogen and 337 3-carboxamide-1H-indoles, whether or not substituted in the indole

338 ring to any extent and substituted to any degree on the 339 carboxamide nitrogen; 340 (M) Cycloalkanemethanone Indoles, whether or not 341 substituted at the nitrogen atom on the indole ring, whether or

S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 14 (csq\tb) 342 not further substituted in the indole ring to any extent, whether

343 or not substituted on the cycloalkane ring to any extent * * *; 344 (e) Depressants. Unless specifically excepted or unless 345 listed in another schedule, any material, compound, mixture, or 346 preparation which contains any quantity of the following 347 substances having a depressant effect on the central nervous

348 system, including their salts, isomers, and salts of isomers, 349 whenever the existence of such salts, isomers, and salts of 350 isomers is possible within the specific chemical designation: 351 (1) Clonazolam, 352 6-(2-chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3- 353 a][1,4]; 354 (2) Flualprazolam,

355 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3- 356 a][1,4]benzodiazepine; 357 (3) Flubromazepam, 358 7-bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 359 (4) Flubromazolam,

360 8-bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3- 361 a][1,4]benzodiazepin;

362 ( * * *5) Gamma-hydroxybutyric acid (other names 363 include: GHB, gamma-hydroxybutyrate; 4-hydroxybutyrate; 364 4-hydroxybutanoic acid; ; sodium oxybutyrate);

365 ( * * *6) ; 366 ( * * *7) .

S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 15 (csq\tb) 367 (f) . Any material, compound, mixture or 368 preparation which contains any quantity of the following central 369 nervous system stimulants including optical salts, isomers and 370 salts of isomers unless specifically excepted or unless listed in 371 another schedule: 372 (1) ;

373 (2) N- (also known as BZP and 374 1-benzylpiperazine); 375 (3) ; 376 (4) ; 377 (5) ; 378 (6) 4-methylaminorex (also known as 379 2-amino-4-methyl-5-phenyl-2-);

380 (7) N-ethylamphetamine; 381 (8) Any material, compound, mixture or preparation 382 which contains any quantity of N,N-. (Other 383 names include: N,N,-alpha-trimethyl-benzeneethanamine and 384 N,N-alpha-trimethylphenethylamine);

385 (9) Synthetic . (A) Unless listed in 386 another schedule, any compound other than that is

387 structurally derived from 2-Amino-1-phenyl-1-propanone by 388 modification in any of the following ways: 389 (i) By substitution in the phenyl ring to any 390 extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide

S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 16 (csq\tb) 391 substituents, whether or not further substituted in the phenyl 392 ring by one or more other univalent substituents; 393 (ii) By substitution at the 3-position with 394 an alkyl substituent; 395 (iii) By substitution at the nitrogen atom 396 with alkyl or dialkyl groups, or by inclusion of the nitrogen atom

397 in a cyclic structure. 398 (B) The compounds covered in this paragraph (9) 399 include, but are not limited to, any material, compound, mixture 400 or preparation which contains any quantity of a synthetic 401 cathinone found in any of the following compounds, whether or not 402 substituted to any extent, or any of these compounds which contain 403 any synthetic cathinone, or salts, isomers, or salts of isomers,

404 whenever the existence of such salts, isomers or salts of isomers 405 is possible, unless specifically excepted or listed in another 406 schedule: 407 (i) 4-methyl-N-ethylcathinone ("4-MEC"); 408 (ii) 4-methyl-alpha-pyrrolidinopropiophenone

409 ("4-MePPP"); 410 (iii) Alpha-pyrrolidinopentiophenone

411 ("α-PVP"); 412 (iv) 413 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (""); 414 (v) 2-(methylamino)-1-phenylpentan-1-one 415 ("");

S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 17 (csq\tb) 416 (vi) 417 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one 418 (""); 419 (vii) 4-fluoro-N-methylcathinone ("4-FMC"); 420 (viii) 3-fluoro-N-methylcathinone ("3-FMC"); 421 (ix)

422 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (""); 423 (x) Alpha-pyrrolidinobutiophenone ("α-PBP"); 424 and 425 (xi) 426 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one 427 (N-ethylpentylone, ephylone).

428 SECTION 2. Section 41-29-115, Mississippi Code of 1972, is 429 amended as follows: 430 41-29-115. (a) The controlled substances listed in this 431 section, by whatever official name, common or usual name, chemical 432 name, or brand name designated, are included in Schedule II.

433 SCHEDULE II

434 (b) Substances, vegetable origin or chemical synthesis. 435 Unless specifically excepted or unless listed in other schedules,

436 any of the following substances, whether produced directly or 437 indirectly by extraction from substances of vegetable origin, or 438 independently by means of chemical synthesis, or by combination of 439 extraction and chemical synthesis:

S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 18 (csq\tb) 440 (1) Opium and opiate, and any salt, compound, 441 derivative, or preparation of opium or opiate, excluding 442 , -derived , , 443 , , , , and 444 , but including the following: 445 (i) Codeine;

446 (ii) ; 447 (iii) ; 448 (iv) Etorphine hydrochloride; 449 (v) Granulated opium; 450 (vi) , whether alone or in combination 451 with any material, compound, mixture or preparation; 452 (vii) ;

453 (viii) ; 454 (ix) Morphine; 455 (x) Opium extracts; 456 (xi) Opium fluid extracts; 457 (xii) ;

458 (xiii) ; 459 (xiv) ;

460 (xv) Powdered opium; 461 (xvi) Raw opium; 462 (xvii) Thebaine; 463 (xviii) Tincture of opium;

S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 19 (csq\tb) 464 (2) Any salt, compound, isomer, derivative, or 465 preparation thereof which is chemically equivalent or identical 466 with any of the substances referred to in paragraph (1), but not 467 including the isoquinoline alkaloids of opium; 468 (3) Opium poppy and poppy straw; 469 (4) leaves and any salt, compound, derivative, or

470 preparation of or coca leaves, including cocaine and 471 ecgonine and any salt, compound, derivative, isomer, or 472 preparation thereof which is chemically equivalent or identical 473 with any of these substances, but not including: 474 (i) Decocainized coca leaves or extraction of coca 475 leaves, which extractions do not contain cocaine or ecgonine; or 476 (ii) ;

477 (5) Concentrate of poppy straw (the crude extract of 478 poppy straw in either liquid, solid or powder form which contains 479 the phenanthrene alkaloids of the opium poppy).

480 (c) Opiates. Any of the following opiates, including their 481 isomers, esters, ethers, salts, and salts of isomers, whenever the

482 existence of these isomers, esters, ethers and salts is possible 483 within the specified chemical designation, dextrorphan and

484 levopropoxyphene excepted: 485 (1) ; 486 (2) Alphaprodine; 487 (3) ; 488 (4) ;

S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 20 (csq\tb) 489 (5) Bulk (nondosage forms); 490 (6) ; 491 (7) ; 492 (8) ; 493 (9) Fentanyl; 494 (10) ;

495 (11) Levo-alphacetylmethadol 496 (levo-alpha-acetylmethadol, levomethadyl acetate, LAAM); 497 (12) ; 498 (13) ; 499 (14) ; 500 (15) ; 501 (16) Methadone-intermediate,

502 4-cyano-2-dimethylamino-4,4-diphenyl ; 503 (17) Moramide-intermediate, 504 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic acid; 505 (18) (meperidine); 506 (19) Pethidine-Intermediate-A,

507 4-cyano-1-methyl-4-phenylpiperidine; 508 (20) Pethidine-Intermediate-B,

509 ethyl-4-phenylpiperidine-4-carboxylate; 510 (21) Pethidine-Intermediate-C, 511 1-methyl-4-phenylpiperidine-4-carboxylic acid; 512 (22) ; 513 (23) ;

S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 21 (csq\tb) 514 (24) Racemethorphan; 515 (25) ; 516 (26) ; 517 (27) ; 518 (28) ; 519 (29) Thiafentanil, methyl

520 4-(2-methoxy-N-phenylacetamido)-1-(2-(thiophen-2- 521 yl)ethyl)piperidine-4-carboxylate), also known as 522 4-(methoxycarbonyl)-4-(N-phenmethoxyacetamido)-1-[2-(thienyl)ethyl 523 ]piperidine.

524 (d) Stimulants. Any material, compound, mixture, or 525 preparation which contains any quantity of the following 526 substances:

527 (1) Amphetamine, its salts, optical isomers, and salts 528 of its optical isomers; 529 (2) and its salts; 530 (3) Any substance which contains any quantity of 531 , including its salts, isomers, and salts of

532 isomers; 533 (4) and its salts;

534 (5) , its salts, isomers and salts of 535 isomers.

536 (e) Depressants. Unless specifically exempted or unless 537 listed in another schedule, any material, compound, mixture, or

S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 22 (csq\tb) 538 preparation which contains any quantity of the following 539 substances: 540 (1) ; 541 (2) ; 542 (3) ; 543 (4) .

544 (f) Hallucinogenic substances. 545 (1) Dronabinol oral solution 546 [(-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC)]; 547 (2) Nabilone [other names include: 548 (+/-)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a- 549 hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo(b,d)pyran-9-one].

550 (g) Immediate precursors. Unless specifically excepted or 551 unless listed in another schedule, any material, compound, 552 mixture, or preparation which contains any quantity of the 553 following substances: 554 (1) Amphetamine and methamphetamine immediate 555 precursor: Phenylacetone (other names include:

556 phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl 557 ketone);

558 (2) Phencyclidine immediate precursors: 559 (i) 1-phenylcyclohexylamine; 560 (ii) 1-piperidinocyclohexanecarbonitrile (PCC); 561 (3) Fentanyl immediate precursor: 562 4-anilino-N-phenethyl-4-piperidine (ANPP).

S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 23 (csq\tb) 563 (h) Any material, compound, mixture or preparation which 564 contains any quantity of a Schedule II controlled substance and is 565 listed as an exempt substance in 21 CFR, Section 1308.24 or 566 1308.32, shall be exempted from the provisions of the Uniform 567 Controlled Substances Law.

568 SECTION 3. Section 41-29-119, Mississippi Code of 1972, is 569 amended as follows: 570 41-29-119. (A) The controlled substances listed in this 571 section are included in Schedule IV.

572 SCHEDULE IV 573 (a) Narcotic drugs. Unless specifically excepted or 574 unless listed in another schedule, any material, compound, mixture 575 or preparation which contains limited quantities of the following

576 narcotic drugs, or any salts thereof: 577 (1) Not more than one (1) milligram of difenoxin 578 and not less than twenty-five (25) micrograms of sulfate 579 per dosage unit; 580 (2) Dextropropoxyphene, including its salts

581 (Darvon, Darvon-N; also found in Darvon compound and Darvocet-N, 582 etc.);

583 (3) 584 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its 585 salts, optical and geometric isomers and salts of these isomers 586 (including ).

S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 24 (csq\tb) 587 (b) Depressants. Any material, compound, mixture or 588 preparation which contains any quantity of the following 589 substances: 590 (1) ; 591 (2) ; 592 (3) ;

593 (4) Brexanolone, 3[alpha]-hydroxy-5[alpha]- 594 pregnan-20-one;

595 ( * * *5) ; 596 ( * * *6) ; 597 ( * * *7) ; 598 ( * * *8) betaine; 599 ( * * *9) ;

600 ( * * *10) and its salts, but 601 does not include chlordiazepoxide hydrochloride and clidinium 602 or chlordiazepoxide and esterified estrogens;

603 ( * * *11) ;

604 ( * * *12) ;

605 ( * * *13) ; 606 ( * * *14) ;

607 ( * * *15) ; 608 ( * * *16) ; 609 ( * * *17) ; 610 ( * * *18) ; 611 ( * * *19) ;

S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 25 (csq\tb) 612 ( * * *20) ; 613 ( * * *21) ; 614 ( * * *22) ; 615 ( * * *23) ; 616 ( * * *24) ; 617 ( * * *25) ;

618 ( * * *26) ; 619 ( * * *27) ; 620 ( * * *28) ; 621 ( * * *29) ; 622 ( * * *30) ; 623 ( * * *31) ; 624 ( * * *32) ;

625 ( * * *33) ; 626 ( * * *34) ; 627 ( * * *35) ; 628 ( * * *36) ;

629 ( * * *37) ;

630 ( * * *38) ; 631 ( * * *39) ;

632 ( * * *40) ; 633 ( * * *41) Nordiazepam; 634 ( * * *42) ; 635 ( * * *43) ; 636 ( * * *44) ;

S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 26 (csq\tb) 637 ( * * *45) ; 638 ( * * *46) ; 639 ( * * *47) ; 640 ( * * *48) ; 641 ( * * *49) ; 642 ( * * *50) ;

643 ( * * *51) ; 644 ( * * *52) ; 645 ( * * *53) ; 646 ( * * *54) ; 647 ( * * *55) ; 648 ( * * *56) . 649 (c) .

650 (d) Lorcaserin. Any material, compound, mixture, or 651 preparation which contains any quantity of Lorcaserin, including 652 its salts, isomers, and salts of such isomers, whenever the 653 existence of such salts, isomers, and salts of isomers is 654 possible.

655 (e) Stimulants. Any material, compound, mixture or 656 preparation which contains any quantity of the following

657 substances: 658 (1) ((+/-) Norpseudoephedrine); 659 (2) Diethylpropion; 660 (3) ; 661 (4) ;

S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 27 (csq\tb) 662 (5) ; 663 (6) ; 664 (7) ; 665 (8) (including any organometallic 666 complexes and chelates thereof); 667 (9) ;

668 (10) ; 669 (11) ; 670 (12) Solriamfetol (2-amino-3-phenylpropyl 671 or (R)-2-amino-3-phenylpropyl carbamate hydrochloride); 672 (13) SPA ((-)-1-dimethylamino-1,2-diphenylethane).

673 (f) Other substances. 674 (1) ; 675 (2) Butorphanol (including its optical isomers); 676 (3) 677 (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-oxopr 678 opyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-meth 679 oxybenzoic acid); (including its optical isomers) and its salts,

680 isomers, and salts of isomers. 681 (B) Any material, compound, mixture or preparation which

682 contains any quantity of a Schedule IV controlled substance and is 683 listed as an exempt substance in 21 CFR, Section 1308.22, 1308.24, 684 1308.26, 1308.32 or 1308.34, shall be exempted from the provisions 685 of the Uniform Controlled Substances Law.

S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 PAGE 28 (csq\tb) 686 SECTION 4. This act shall take effect and be in force from 687 and after its passage.

S. B. No. 2694 *SS08/R210* ~ OFFICIAL ~ 20/SS08/R210 ST: Uniform Controlled Substances Act; revise PAGE 29 (csq\tb) schedules.